| CD274 Expression26 |
|---|
| (diagnostic) | Malignant Breast Neoplasm | Diagnostic | A | Supports Positive | 4 | submitted | EID11484The results and published literature suggest that in addition to guiding targeted therapy selection, comprehensive genomic profiling shows the potential to identify genomic alterations linked to respo… (full text at CIViC) PMID 33314633 · Sivapiragasam et al., 2021 · Open in CIViC | civic |
| (prognostic) | Lung Non-Small Cell CarcinomaCURATED_BROADER | Prognostic | B | Does Not Support Poor Outcome | 4 | accepted | EID701This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC. PMID 26664143 · Zhong et al., 2015 · Open in CIViC | civic |
| 〃 | Malignant NeoplasmALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID5507A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expression results in poor overall survival (HR = 1.58, P <.001) and poor disease free/progression free s… (full text at CIViC) PMID 28471952 · Wang et al., 2017 · Open in CIViC | civic |
| 〃 | Lung Squamous Cell Carcinoma | Prognostic | B | Supports Better Outcome | 3 | accepted | EID702In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study). PMID 26313362 · Schmidt et al., 2015 · Open in CIViC | civic |
| 〃 | Ovarian Serous AdenocarcinomaALIAS | Prognostic | B | Supports Better Outcome | 3 | accepted | EID703High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases). PMID 26625204 · Darb-Esfahani et al., 2016 · Open in CIViC | civic |
| 〃 | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1274Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). … (full text at CIViC) PMID 27086918 · Chowdhury et al., 2016 · Open in CIViC | civic |
| 〃 | Gastric CarcinomaALIAS | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1275465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous … (full text at CIViC) PMID 27009855 · Böger et al., 2016 · Open in CIViC | civic |
| 〃 | Malignant Breast Neoplasm | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID4855In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic association of PD-L1 expression in breast cancer. The combined hazard ratio (HR) for PD-L1 overexpression … (full text at CIViC) PMID 28430626 · Zhang et al., 2017 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 2 | accepted | EID97574 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively analyzed for PD-L1 expression and CD8+ tumour-infiltrating lymphocytes (TILs) density (IHC). CD8+ TIL de… (full text at CIViC) PMID 26771872 · Tokito et al., 2016 · Open in CIViC | civic |
| 〃 | Malignant Breast Neoplasm | Prognostic | B | Supports Poor Outcome | 2 | accepted | EID4844A meta-analysis of the role of PD-L1 expression in breast cancer found nine relevant studies with a total 8583 patients. PD-L1 expression was found to be associated with several poor prognostic indica… (full text at CIViC) PMID 28079291 · Wang et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant NeoplasmALIAS | Prognostic | B | Supports Better Outcome | 2 | accepted | EID4856PD-L1 is not only expressed in tumor cells (TCs) but also upregulated in tumor-infiltrating immune cells (TIICs). This meta-analysis evaluated the prognostic value of PD-L1 expression in TIICs in diff… (full text at CIViC) PMID 28453554 · Zhao et al., 2017 · Open in CIViC | civic |
| Atezolizumab | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1172Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 ex… (full text at CIViC) PMID 26970723 · Fehrenbacher et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID9009Within a phase one clinical trial, the response to atezolizumab from 938 patients with non-small cell carcinoma indicated high PD-L1 expression corresponded independently to response to atezolizumab o… (full text at CIViC) PMID 30297397 · Kowanetz et al., 2018 · Open in CIViC | civic |
| 〃 | Bladder Urothelial Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 2 | submitted | EID9886Within a multicentre, open-label, phase 3 randomised control trial, investigation of the potential biomarker PD-L1 was found not to potentiate anti-tumor effects in response to atezolizumab in metasta… (full text at CIViC) PMID 29268948 · Powles et al., 2018 · Open in CIViC | civic |
| Nivolumab | Malignant NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1517Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH f… (full text at CIViC) PMID 22658127 · Topalian et al., 2012 · Open in CIViC | civic |
| 〃 | Malignant Nasopharyngeal NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 1 | submitted | EID9010In a Clinic Phase 2 Consortium, 44 patients with metastatic nasopharyngeal carcinoma had an overall response rate (ORR) to nivolumab of 20.5%; 1 complete response lasting over 12 months; 8 partial res… (full text at CIViC) PMID 29584545 · Ma et al., 2018 · Open in CIViC | civic |
| Ipilimumab + NivolumabCombination | Melanoma | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID1615A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed… (full text at CIViC) PMID 23724867 · Wolchok et al., 2013 · Open in CIViC | civic |
| Nivolumab + PembrolizumabSubstitutes | Melanoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID704Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active dru… (full text at CIViC) PMID 26086854 · Carbognin et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID743Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targe… (full text at CIViC) PMID 26086854 · Carbognin et al., 2015 · Open in CIViC | civic |
| 〃 | Melanoma | Predictive | B | Supports Sensitivity Response | 1 | submitted | EID9008Within a preclinical trial, 37 patients with metastatic melanoma showed a limited number of cases that responded to anti-PD-1 antibodies in correlation to higher immunohistochemical PD-L1 expression. … (full text at CIViC) PMID 27491654 · Cho et al., 2016 · Open in CIViC | civic |
| Atezolizumab + Avelumab + Nivolumab + PembrolizumabSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1167Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining ≥1%), had … (full text at CIViC) PMID 26918451 · Passiglia et al., 2016 · Open in CIViC | civic |
| Atezolizumab + Avelumab + Durvalumab + Nivolumab + PembrolizumabSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID4857In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to bet… (full text at CIViC) PMID 28472902 · Aguiar et al., 2017 · Open in CIViC | civic |
| Pembrolizumab | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID5811PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. PMID 25891174 · Garon et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1733This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation o… (full text at CIViC) PMID 27718847 · Reck et al., 2016 · Open in CIViC | civic |
| 〃 | Merkel Cell Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 2 | accepted | EID1578Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression. The response ra… (full text at CIViC) PMID 27093365 · Nghiem et al., 2016 · Open in CIViC | civic |
| Radiation Therapy | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 4 | accepted | EID3000Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamo… (full text at CIViC) PMID 28476872 · Skinner et al., 2017 · Open in CIViC | civic |